Aug 2026· International Journal of Molecular Sciences· Vol 27· 0 citations· 66 references
Medicine
TL;DR
This computational study identifies several candidate lncRNAs associated with clinical outcomes in breast cancer, which should be interpreted as preliminary candidates, which require future validation and functional studies to determine their biological roles and evaluate their potential as prognostic biomarkers.
Abstract
Functional studies have shown that long noncoding RNAs (lncRNAs) play different roles in gene expression regulation, acting as epigenetic factors. Accumulating evidence indicates that lncRNAs modulate diverse biological processes, and their altered expression is associated with the development and progression of cancer, including BC. Here, aiming to identify lncRNAs associated with breast cancer, we performed a re-analysis of the expression data from 1071 tumors of eligible patients in the LACRN-MPBC Study. Using normalized data, we compared the expression profiles of triple-negative breast cancer (TNBC; 170 cases) and a heterogeneous group of non-TNBC tumors (782 cases). A total of 59 differentially expressed lncRNAs (DELncRNAs) could be identified based on the criteria of |log2FC| ≥ 1 and FDR < 0.05, using the DESeq2 R package. In the Kaplan–Meier survival analysis, we identified DELncRNAs that affect disease-free survival and/or overall survival, with eight of them in TNBC and 27 in non-TNBC patients. Multivariate Cox proportional-hazards models were used to evaluate independent predictors of survival. Two DELncRNAs, VLDLR-AS1 and PART1, were identified as independent prognostic markers for TNBC patients, while seven (LINC00239, FAM30A, LINC00842, LINC01315, EGOT, LY6E-DT, and SLC25A21-AS1) were independent prognostic markers for non-TNBC patients. Our computational study identifies several candidate lncRNAs associated with clinical outcomes in breast cancer. However, the DELncRNAs identified here should be interpreted as preliminary candidates, which require future validation and functional studies to determine their biological roles and evaluate their potential as prognostic biomarkers.
This study found that LINC02257 and LINC00659 are upregulated in BC and are associated with malignancy-related genes and patient survival, suggesting their potential as therapeutic targets and prognostic biomarkers.
Fatemeh Badzohre, Azin Azadfekr, Farnoosh Akbari et al.· Current Genetic Medicine Rep...· 0 citations
These findings nominate FAM83A-AS2 and AC012213.1 as candidate epigenetically associated prognostic lncRNAs in LUAD, warranting validation in independent cohorts and functional studies.
S. M. Al Sium, Mahafujul Islam Quadery Tonmoy, Dhirendra Nath Barman et al.· Bioinformatics Advances· 0 citations
The established eight-ARlncRNA signature serves as a robust prognostic tool, effectively predicting patient survival and mirroring the heterogeneity of the tumor immune landscape, and offers potential guidance for personalizing therapeutic strategies in glioma.
Yuting Ouyang, Rui Han, An-Qi Song et al.· Discover Oncology· 0 citations
A clinically applicable RNA methylation-related lncRNAs signature is developed that effectively predicts HCC prognosis and therapeutic response and provides valuable insights for risk stratification and may guide personalized treatment decisions in HCC management.
Yunchuan Yang, Xiang Ma, Chi Zhou et al.· Egyptian Liver Journal· 0 citations
This network modelling approach establishes that combinatorial modelling of coding and non-coding elements outperforms individual approaches, providing a robust framework for prognostic stratification and therapeutic targeting in cervical cancer.
V. B. Navya, Geethu Muraleedharan, P. K. Fasna et al.· Biochemical and Biophysical...· 0 citations
This work put forward LSNP regulated gene expression based breast and ovarian cancer risk prediction model LsGCRPred (LSNP-Gene Interaction Based Cancer Risk Prediction Model), which accounts for the tissue-specificity of lncRNAs as well the benefit for individuals with predisposing conditions.